TransMedics Group (NASDAQ:TMDX) Earns "Buy" Rating from Canaccord Genuity Group

Key Points

• TransMedics Group's stock received a "buy" rating from Canaccord Genuity Group, with a price target of $142.00, indicating a potential upside of 27.51%.
• The company reported strong quarterly earnings, achieving $0.92 EPS against estimates of $0.48, with a revenue growth of 37.7% year-over-year.
• Institutional investors hold 99.67% of TransMedics Group's stock, highlighting significant interest from large investment firms, including a 112.7% increase in stake by Zevenbergen Capital Investments LLC.

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Canaccord Genuity Group in a research report issued on Tuesday,Benzinga reports. They currently have a $142.00 price objective on the stock. Canaccord Genuity Group's target price would indicate a potential upside of 27.51% from the company's current price.

TMDX has been the subject of a number of other reports. Oppenheimer upped their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Morgan Stanley upped their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Weiss Ratings reissued a "hold (c)" rating on shares of TransMedics Group in a report on Wednesday, October 8th. Finally, Jefferies Financial Group began coverage on shares of TransMedics Group in a report on Monday. They issued a "buy" rating and a $145.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $127.18.

TransMedics Group Stock Down 0.3%

NASDAQ:TMDX traded down $0.35 during trading hours on Tuesday, hitting $111.36. The stock had a trading volume of 74,142 shares, compared to its average volume of 1,255,962. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $145.50. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a market cap of $3.80 billion, a PE ratio of 57.68 and a beta of 2.08. The business has a 50 day simple moving average of $116.88 and a two-hundred day simple moving average of $112.70.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Analysts predict that TransMedics Group will post 1 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently added to or reduced their stakes in the stock. Zevenbergen Capital Investments LLC raised its stake in TransMedics Group by 112.7% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company's stock valued at $29,006,000 after purchasing an additional 136,995 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of TransMedics Group by 17.5% in the 3rd quarter. Voya Investment Management LLC now owns 10,694 shares of the company's stock valued at $1,200,000 after purchasing an additional 1,590 shares in the last quarter. Corient Private Wealth LLC bought a new position in shares of TransMedics Group in the second quarter valued at about $307,000. Texas Permanent School Fund Corp raised its holdings in shares of TransMedics Group by 124.1% in the second quarter. Texas Permanent School Fund Corp now owns 22,118 shares of the company's stock valued at $2,964,000 after buying an additional 12,249 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of TransMedics Group by 48.5% in the second quarter. Osaic Holdings Inc. now owns 21,116 shares of the company's stock valued at $2,830,000 after buying an additional 6,899 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.